- Home
- TENX vs SONN Comparison
TENX vs SONN Comparison
Compare TENX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- SONN
- Stock Information
- Founded
- TENX 1967
- SONN N/A
- Country
- TENX United States
- SONN United States
- Employees
- TENX N/A
- SONN N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- SONN Health Care
- Exchange
- TENX Nasdaq
- SONN Nasdaq
- Market Cap
- TENX 31.9M
- SONN 32.4M
- IPO Year
- TENX N/A
- SONN N/A
- Fundamental
- Price
- TENX $7.70
- SONN $4.35
- Analyst Decision
- TENX Strong Buy
- SONN Strong Buy
- Analyst Count
- TENX 2
- SONN 1
- Target Price
- TENX $17.00
- SONN $20.00
- AVG Volume (30 Days)
- TENX 59.3K
- SONN 770.8K
- Earning Date
- TENX 11-12-2025
- SONN 12-16-2025
- Dividend Yield
- TENX N/A
- SONN N/A
- EPS Growth
- TENX N/A
- SONN N/A
- EPS
- TENX N/A
- SONN N/A
- Revenue
- TENX N/A
- SONN $1,000,000.00
- Revenue This Year
- TENX N/A
- SONN $5,376.22
- Revenue Next Year
- TENX N/A
- SONN N/A
- P/E Ratio
- TENX N/A
- SONN N/A
- Revenue Growth
- TENX N/A
- SONN 1689.52
- 52 Week Low
- TENX $4.63
- SONN $1.08
- 52 Week High
- TENX $8.24
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- TENX 60.46
- SONN 47.49
- Support Level
- TENX $7.30
- SONN $4.05
- Resistance Level
- TENX $8.05
- SONN $5.14
- Average True Range (ATR)
- TENX 0.43
- SONN 0.97
- MACD
- TENX 0.05
- SONN 0.00
- Stochastic Oscillator
- TENX 79.87
- SONN 47.00
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.